Antitumor β-glucan from the cultured fruit body of Agaricus blazei

被引:181
作者
Ohno, N
Furukawa, M
Miura, NN
Adachi, Y
Motoi, M
Yadomae, T
机构
[1] Tokyo Univ Pharm & Life Sci, Sch Pharm, Lab Immunopharmacol Microbial Prod, Tokyo 1920392, Japan
[2] Toei Pharmaceut Co Ltd, Tokyo 1810011, Japan
关键词
beta-glucan; Agaricus blazei; immunomodulation; antitumor activity;
D O I
10.1248/bpb.24.820
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Agaricus blazei is a medically important mushroom widely eaten and prescribed in Japan. Polysaccharide fractions were prepared from cultured A. blazei by repeated extraction with hot water (AgHWE), cold NaOH (AgCA), and then hot NaOH (AgHA). By chemical, enzymic, and NMR analyses, the primary structures of AgHWE, AgCA, and AgHA were mainly composed of 1,6-beta -glucan. Among these fractions, the NaOH extracts showed antitumor activity against the solid form of Sarcoma 180 in ICR mice. To demonstrate the active component in these fractions, several chemical and enzymic treatments were applied. These fractions were found to be i) neutral beta -glucan passing DEAE-Sephadex A-25, ii) resistant to periodate oxidation (I/B) and subsequent partial acid hydrolysis (I/B/H), iii) resistant to a 1,3-beta -glucanase, zymolyase, before I/B, but sensitive after I/B/H, In addition, after I/B/H treatment of the neutral fraction of AgCAE, a signal around 86 ppm attributable to 1,3-beta- glucosidic linkage was detectable in the C-13-NMR spectrum. These facts strongly suggest that a highly branched 1,3-beta -glucan segment forms the active center of the antitumor activity.
引用
收藏
页码:820 / 828
页数:9
相关论文
共 51 条
[1]  
ADACHI Y, 1994, BIOL PHARM BULL, V17, P1508
[2]  
ADACHI Y, 1990, CHEM PHARM BULL, V38, P988
[3]   UPDATE ON THE IMMUNOMODULATING ACTIVITIES OF GLUCANS [J].
DILUZIO, NR .
SPRINGER SEMINARS IN IMMUNOPATHOLOGY, 1985, 8 (04) :387-400
[4]  
EYNDE BJ, 1997, CURR OPIN IMMUNOL, V9, P684
[5]   Selective tumoricidal effect of soluble proteoglucan extracted from the basidiomycete, Agaricus blazei Murill, mediated via natural killer cell activation and apoptosis [J].
Fujimiya, Y ;
Suzuki, Y ;
Oshiman, K ;
Kobori, H ;
Moriguchi, K ;
Nakashima, H ;
Matumoto, Y ;
Takahara, S ;
Ebina, T ;
Katakura, R .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1998, 46 (03) :147-159
[6]  
Fujimiya Y, 1999, ANTICANCER RES, V19, P113
[7]  
FUJIMOTO S, 1988, BIOTHERAPY, V2, P500
[8]  
Hashimoto T, 1997, BIOL PHARM BULL, V20, P1006
[9]  
Hashimoto T, 1997, DRUG DEVELOP RES, V42, P35, DOI 10.1002/(SICI)1098-2299(199709)42:1<35::AID-DDR3>3.0.CO
[10]  
2-S